Ethanol potentiates valproic acid-induced neural tube defects (NTDs) in mice due to toxicokinetic interactions

1995 ◽  
Vol 9 (5) ◽  
pp. 427-433 ◽  
Author(s):  
M Elmazar
Teratology ◽  
1988 ◽  
Vol 38 (4) ◽  
pp. 313-320 ◽  
Author(s):  
Richard H. Finnell ◽  
Gregory D. Bennett ◽  
Steven B. Karras ◽  
Virginia K. Mohl

2017 ◽  
Vol 112 ◽  
pp. 193
Author(s):  
Ted B. Piorczynski ◽  
S. Marc Lucas ◽  
Britney K. Oxley ◽  
Jason M. Hansen

2009 ◽  
Vol 108 (1) ◽  
pp. 132-148 ◽  
Author(s):  
Måns Jergil ◽  
Kim Kultima ◽  
Anne-Lee Gustafson ◽  
Lennart Dencker ◽  
Michael Stigson

PEDIATRICS ◽  
1983 ◽  
Vol 71 (6) ◽  
pp. 980-980
Author(s):  

In a recent statement entitled, "Valproic Acid: Benefits and Risks" we reported that despite the presence of teratogenic effects in animals there existed only one possible case in man.1 Recently the Centers for Disease Control has reported that the use of valproic acid (Depakene), during the first trimester of pregnancy, may increase the risk of having a child with spina bifids.2 The report, based upon a study undertaken in Rhône-Alpes, France,3,4 quotes an estimated risk of 1.2%. Based upon this information, we believe that a woman who becomes pregnant while on valproic acid should consult with her physician about prenatal testing for neural tube defects. Additional recommendations for the counseling of women who require anticounvulsant treatment during pregnancy have been published previously.5


Sign in / Sign up

Export Citation Format

Share Document